EF Hutton Acquisition Co. I Upgrades UroGen Pharma (NASDAQ:URGN) to “Strong-Buy”

UroGen Pharma (NASDAQ:URGN) was upgraded by equities researchers at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued on Monday, Zacks.com reports.

A number of other research analysts have also recently commented on URGN. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Thursday, October 3rd. Guggenheim began coverage on UroGen Pharma in a research report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $48.38.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $12.26 on Monday. UroGen Pharma has a 52 week low of $10.60 and a 52 week high of $20.70. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. The stock has a market cap of $287.55 million, a price-to-earnings ratio of -3.61 and a beta of 1.11. The business has a 50-day simple moving average of $13.62 and a 200 day simple moving average of $14.40.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. On average, research analysts forecast that UroGen Pharma will post -3.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of URGN. China Universal Asset Management Co. Ltd. raised its holdings in UroGen Pharma by 65.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock valued at $89,000 after buying an additional 2,328 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of UroGen Pharma during the third quarter valued at about $179,000. ProShare Advisors LLC bought a new position in shares of UroGen Pharma during the second quarter valued at about $199,000. Main Street Financial Solutions LLC purchased a new stake in shares of UroGen Pharma during the second quarter worth about $403,000. Finally, Tidal Investments LLC bought a new stake in shares of UroGen Pharma in the first quarter worth about $425,000. Institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.